Humana's CenterWell Pharmacy Partners with Eli Lilly to Expand Employer-Based Access to Obesity Medications
核心洞察
CenterWell Pharmacy (搜索), Humana's specialty pharmacy division, announced a strategic partnership with Eli Lilly to dispense FDA-approved obesity management medications through employer-sponsored carve-out programs.
The initiative addresses rising prescription drug costs for employers, with 79% reporting increased GLP-1 (搜索) usage, while providing more affordable access to weight-loss medications for employees.
The program operates through approved third-party entities where employees receive prescriptions, which are then fulfilled by CenterWell with comprehensive pharmacy services including clinical support and care navigation.
CenterWell Pharmacy (搜索), Humana's specialty and home delivery pharmacy division, has announced a strategic partnership with Eli Lilly to expand access to FDA-approved obesity management medications through employer-focused programs. The initiative targets employer plan-sponsored carve-out programs, addressing the growing challenge of prescription drug costs while improving medication access for employees.
Addressing Rising Healthcare Costs
The partnership comes as employers face significant challenges with prescription drug expenses, which continue to be the fastest-growing component of health benefits. According to CenterWell data, 79% of employers have reported increased usage of GLP-1 (搜索) receptor agonists, highlighting the growing demand for these obesity management therapies.
"Employers continue to tell us they want to better support their employees' health but face real challenges in providing coverage for obesity management medicines," said Kevin Hern, Senior Vice President at Lilly USA. "We're excited to work with organizations that share our commitment to removing friction and providing flexible, transparent solutions for employers to help expand access to obesity management medicines for people who need them."
Program Implementation
The program operates through approved third-party benefit administrators and entities that employers can access for their employees. Some utilize subscription models, while others work through primary care telehealth practices where patients receive prescriptions from healthcare providers.
Once employees meet with prescribers through these approved entities, prescriptions are forwarded to CenterWell Pharmacy (搜索) for fulfillment. Aleata Postell, Senior Vice President of Pharmacy Business Development at CenterWell Pharmacy, explained that patients receive comprehensive pharmacy services, including pharmacist clinical support and care navigators to assist with their health journey.
Strategic Market Position
Bethanie Stein, PharmD, President of Humana's Pharmacy Segment, emphasized the untapped opportunity in employer-based programs. "We've already seen success in expanding access to obesity management medications through direct-to-patient distribution at more affordable price points," she stated. "We at CenterWell Pharmacy (搜索) are pleased to play an important role in standing up a more sustainable approach to distributing valuable weight-loss medications."
The collaboration builds on Eli Lilly's previously announced plans to launch a direct-to-employer GLP-1 (搜索) model, representing a significant shift toward employer-centered healthcare solutions. By integrating obesity management therapies into employer-sponsored programs, the partnership aims to enhance affordability and prescription fulfillment while strengthening employer partnerships in chronic condition management.
Service Delivery Model
The program maintains CenterWell's standard pharmacy operations, including patient engagement notifications when medications are ready and comprehensive clinical support. This approach ensures employees receive the same level of care and service they would expect from traditional pharmacy channels while benefiting from the cost advantages of the employer-sponsored model.
The initiative represents a novel approach to addressing the dual challenges of medication affordability and employer healthcare cost management, potentially serving as a model for other chronic condition therapies in the employer benefits space.